Gonadal Disorders: Clinical Trials

2883 completed, 910 unknown, 814 recruiting, 551 terminated. 1655 Phase 2, 1306 Phase 1, 1207 Not applicable, 549 Phase 3, 291 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	1655	Completed 809, Terminated 238, Recruiting 203, Unknown 185, Active not recruiting 104, Withdrawn 56, Not yet recruiting 55, Suspended 3, Enrolling by invitation 2
Phase 1	1306	Completed 617, Terminated 210, Recruiting 194, Unknown 100, Active not recruiting 97, Withdrawn 52, Not yet recruiting 26, Suspended 9, Enrolling by invitation 1
Not applicable	1207	Completed 550, Unknown 225, Recruiting 181, Not yet recruiting 80, Terminated 60, Active not recruiting 57, Withdrawn 38, Enrolling by invitation 11, Suspended 5
Phase 3	549	Completed 290, Unknown 72, Recruiting 71, Terminated 41, Active not recruiting 40, Not yet recruiting 18, Withdrawn 15, Suspended 2
Phase 4	291	Completed 172, Unknown 55, Terminated 19, Withdrawn 17, Recruiting 15, Not yet recruiting 7, Active not recruiting 4, Enrolling by invitation 1, Suspended 1
Early Phase 1	96	Completed 35, Unknown 17, Withdrawn 13, Terminated 10, Not yet recruiting 8, Recruiting 7, Active not recruiting 4, Enrolling by invitation 1, Suspended 1

Follow Gonadal Disorders: new trials by email Literature Review of Gonadal Disorders trials Research Report on Gonadal Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer	Not applicable	Not yet recruiting	Oncare Madrid	32	2028-05-01	2026-10-08
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries	Phase 2 / Phase 3	Not yet recruiting	VA Office of Research and Development	300	2027-10-01	2026-08-04
A Dose Ranging Study to Examine TDS-Testosterone 5% Testosterone, Pump Sprayer - Hypogonadotropism	Phase 2	Not yet recruiting	Transdermal Delivery Solutions Corp	48	2027-06-01	2026-09-30
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation	Phase 3	Not yet recruiting	ShangHai Ji Ai Genetics & IVF Institute	204	2027-06-01	2026-11-09
PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing	Not applicable	Not yet recruiting	Rachel Miller	200	2027-04-01	2026-09-10
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Not yet recruiting	Daiichi Sankyo	600	2027-03-31	2026-11-13
(Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty (Z)-endoxifen - Precocious Puberty, Gonadotropin-dependent	Phase 2	Not yet recruiting	Atossa Therapeutics, Inc.	6	2027-03-01	2026-10-09
Recover@Home Postoperative Follow-up Study Recovery@home - Hernia, Inguinal, Hernia, Femoral	Not applicable	Not yet recruiting	Icahn School of Medicine at Mount Sinai	194	2027-03-01	2026-07-20
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer	Phase 2	Not yet recruiting	Massachusetts General Hospital	27	2027-02-01	2026-09-22
Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial Time-restricted eating - Polycystic Ovary Syndrome	Not applicable	Not yet recruiting	Joanna Bajerska	84	2027-01-09	2026-10-16
Product Transference Study of Testagen™ TDS®-Testosterone Testagen® TDS Testosterone 5% HypoSpray® - Hypogonadotropism	Phase 2	Not yet recruiting	Transdermal Delivery Solutions Corp	96	2027-01-05	2026-05-27
Helping Young People With Testicular Cancer Using Virtual and Extended Reality Digital tool using extended reality - Testicular Cancer, Testis Cancer	Not applicable	Not yet recruiting	Gustave Roussy, Cancer Campus, Grand Paris	245	2027-01-04	2026-05-06
NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer	Early Phase 1	Not yet recruiting	Base Therapeutics (Shanghai) Co., Ltd.	18	2027-01-01	2026-09-30
Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia exposure to healthcare transition protocol - Congenital Adrenal Hyperplasia		Not yet recruiting	University of Alabama at Birmingham	40	2027-01-01	2026-10-14
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care ICG-Guided Retroperitoneal Sentinel Lymph Node Biopsy, Radical Inguinal Orchiectomy - Testicular Cancer, Testicular Germ Cell Tumor	Not applicable	Not yet recruiting	Heinrich-Heine University, Duesseldorf	171	2027-01-01	2026-07-13
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer	Phase 2	Recruiting	University Health Network, Toronto	96	2026-12-31	2026-10-22
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers	Phase 2 / Phase 3	Not yet recruiting	Shanghai Gynecologic Oncology Group	534	2026-12-31	2026-11-12
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome Synbiotic Supplement, Placebo - PCOS (Polycystic Ovary Syndrome)	Not applicable	Recruiting	Atlas University	32	2026-12-20	2026-10-28
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial Internet-Based Intervention, Interview, Questionnaire Administration - Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm	Not applicable	Not yet recruiting	University of Michigan Rogel Cancer Center	142	2026-12-01	2026-10-15
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer	Phase 2	Not yet recruiting	Medical University of South Carolina	20	2026-12-01	2026-07-22

Showing 20 of 5964. Sign in to see all of them.

Narrower conditions

Ovarian Neoplasms (3271)  ·  Polycystic Ovary Syndrome (956)  ·  Carcinoma, Ovarian Epithelial (787)  ·  Fallopian Tube Neoplasms (785)  ·  Breast Neoplasms (707)  ·  Endometrial Neoplasms (462)  ·  Neoplasms (397)  ·  Uterine Cervical Neoplasms (370)  ·  Carcinoma, Non-Small-Cell Lung (346)  ·  Pancreatic Neoplasms (337)  ·  Colorectal Neoplasms (326)  ·  Hypogonadism (316)  ·  Testicular Neoplasms (295)  ·  Prostatic Neoplasms (283)  ·  Stomach Neoplasms (276)

Broader conditions

Endocrine System Diseases (5924)  ·  Urogenital Diseases (5602)  ·  Female Urogenital Diseases and Pregnancy Complications (5369)  ·  Female Urogenital Diseases (5368)  ·  Genital Diseases (5270)  ·  Genital Diseases, Female (4977)  ·  Adnexal Diseases (4968)  ·  Ovarian Diseases (4934)  ·  Neoplasms (4549)  ·  Neoplasms by Site (3902)  ·  Urogenital Neoplasms (3876)  ·  Endocrine Gland Neoplasms (3860)  ·  Genital Neoplasms, Female (3679)  ·  Neoplasms by Histologic Type (1567)

Interventions

Paclitaxel (390)  ·  Carboplatin (388)  ·  Bevacizumab (209)  ·  Metformin (175)  ·  Cisplatin (127)  ·  Gemcitabine (125)  ·  liposomal doxorubicin (123)  ·  pembrolizumab (120)  ·  Cyclophosphamide (110)  ·  Testosterone (107)  ·  Topotecan (105)  ·  olaparib (101)  ·  niraparib (74)  ·  Taxes (72)  ·  Letrozole (71)

Sponsors

National Cancer Institute (NCI) (202)  ·  Memorial Sloan Kettering Cancer Center (88)  ·  M.D. Anderson Cancer Center (86)  ·  Gynecologic Oncology Group (77)  ·  AstraZeneca (66)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (46)  ·  Eli Lilly and Company (41)  ·  Cairo University (39)  ·  Dana-Farber Cancer Institute (37)  ·  Mayo Clinic (37)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (36)  ·  Massachusetts General Hospital (36)  ·  Assiut University (33)  ·  University of Virginia (33)  ·  University Health Network, Toronto (31)

Countries

United States (2682)  ·  China (601)  ·  France (437)  ·  Italy (405)  ·  United Kingdom (392)  ·  Canada (366)  ·  Spain (341)  ·  Germany (265)  ·  Belgium (231)  ·  South Korea (216)  ·  Australia (212)  ·  Netherlands (190)  ·  Denmark (185)  ·  Turkey (Türkiye) (169)  ·  Egypt (161)

Top investigators

Lei Li, M.D. (14)  ·  Stefano Palomba, MD (14)  ·  Paul Sabbatini, MD (13)

Results publications

PMID 37185961, PMID 37407274, PMID 35170751, PMID 27008889, PMID 37462232, PMID 39695768, PMID 19238149, PMID 30633128, PMID 38224135, PMID 20818904, PMID 23922302, PMID 26961146, PMID 29342393, PMID 29486615, PMID 35537408, PMID 36512649, PMID 36978128, PMID 39019698, PMID 41868592, PMID 42014131, PMID 42693220, PMID 14688154, PMID 16394300, PMID 18158291, PMID 20424285, PMID 21324454, PMID 21941283, PMID 26707054, PMID 28981994, PMID 30796792, PMID 31132118, PMID 31547562, PMID 32034419, PMID 32195207, PMID 33347618, PMID 33527139, PMID 33538338, PMID 34904813, PMID 35262624, PMID 35397664, PMID 40132910, PMID 40785326, PMID 41044356, PMID 12826431, PMID 16882940, PMID 16966687, PMID 17000396, PMID 17949799, PMID 18480812, PMID 19282241

NIH funding

U10CA027469 (59), U10CA180868 (45), 2023 (39), 2018 (27), 2025 (23), 2009 (21), 2017 (20), 2008 (19), 2015 (19), P30CA033572 (19), 2016 (18), P30CA015083 (14), 2019 (13), U10CA101165 (11), P30CA043703 (10)